Effect of BIBT 986 Followed by BIBT 986 Given as IV Infusion on Tissue Factor Triggered Coagulation in Healthy Male Volunteers

NCT02259881 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Low dose of BIBT 986 CL, per i.v. infusion
DRUG: Medium dose of BIBT 986 CL, per i.v. infusion
DRUG: High dose of BIBT 986 CL, per i.v. infusion
DRUG: Placebo
DRUG: Lipopolysaccharide (LPS), single i.v. bolus

Sponsor

Boehringer Ingelheim